Latest Breaking News On - German cancer society - Page 4 : comparemela.com

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy

Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Thomas heinemanTimothy mccarthyJon pattonSara lonardiDirk arnoldMatt coffeyCompany contactOncolytics biotechInternational multidisciplinary anal cancer conferenceGerman cancer societyOncolytics biotech incSecurities exchangeAnal cancer cohortAtezolizumab has metSuccess criteriaAsklepios tumorzentrum hamburg

Reducing Breast Cancer Risk: The Power of a Healthy Diet with 24vitaPrevention

Reducing Breast Cancer Risk: The Power of a Healthy Diet with 24vitaPrevention
archyde.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from archyde.com Daily Mail and Mail on Sunday newspapers.

Judith braunGerman cancer societyGerman cancer society breastBreast cancer germanyUniversidad de navarra

Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study

Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Matt coffeyTimothy mccarthyJon pattonThomas heinemanOncolytics biotechOncolytics biotech incSecurities exchangeGerman cancer societyCompany contactEuropean society for medical oncologyAchieves success criteriaThird line colorectal cancer cohortEuropean societyMedical oncologyChief executive officerChief medical officer

Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO

7.2 months mPFS and 10.6 months interim median OS surpass historical outcomes by ≥ 25% T-cell expansion data correlate with tumor response, providing important proof-of-concept SAN DIEGO and.

Thomas heinemanTimothy mccarthyJon pattonMatt coffeyCompany contactEuropean society for medical oncologySecurities exchangeOncolytics biotechOncolytics biotech incGerman cancer societyMedical oncologyChief executive officerResponse rateDisease control rateCell populationsChief medical officer

Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023

Preliminary updated PDAC data show 6-month overall survival rate of 82% Results from pelareorep combination in mCRC met the Stage 1 success criteria SAN DIEGO and CALGARY, AB, Oct. 16, 2023.

Timothy mccarthyJon pattonGerman cancer societyOncolytics biotechMadrid conference centerEuropean society for medical oncologyOncolytics biotech incCompany contactSecurities exchangeEuropean societyMedical oncologyConference centerPublication numberSecurities exchange act